{"schema_version":"secwatch.filing_event.v1","accession":"0001104659-21-132088","form_type":"8-K","ticker":"KNSA","cik":"0001730430","company_name":"Kiniksa Pharmaceuticals International, plc","filed_at":"2021-11-01T23:59:59+00:00","discovered_at":"2026-05-14T18:04:13.867843+00:00","generated_at":"2026-06-28T15:48:50.331851+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"Kiniksa reports Q3 ARCALYST net revenue of $12.1M; net loss narrows to $30.5M","bullets":["ARCALYST net revenue $12.1M in Q3 2021; Q4 2021 revenue guided to $16-17M.","Net loss of $30.5M improved from $43.8M in Q3 2020; operating expenses $42.8M.","Cash and investments $200.2M, no debt; cash expected to fund operations into 2023.","Mavrilimumab Phase 3 in COVID-19 ARDS data expected Q1 2022; vixarelimab Phase 2b data in prurigo nodularis expected 2H 2022.","Over 200 physicians prescribed ARCALYST for recurrent pericarditis since approval; >190M lives covered."],"urls":{"canonical":"https://secwatch.observer/filing/0001104659-21-132088","json":"https://secwatch.observer/filing/0001104659-21-132088.json","markdown":"https://secwatch.observer/filing/0001104659-21-132088.md","text":"https://secwatch.observer/filing/0001104659-21-132088.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1730430/000110465921132088/0001104659-21-132088-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1730430/000110465921132088/tm2131179d1_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-28T15:48:50.331851+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}